We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+20.47%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$239M
AUM Growth
+$36M
Cap. Flow
+$7.18M
Cap. Flow %
3%
Top 10 Hldgs %
37.89%
Holding
60
New
11
Increased
16
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
ASRT
Assertio
ASRT
+$5.63M
2
RLYP
RELYPSA INC COM
RLYP
+$4.74M
3
SAGE
Sage Therapeutics
SAGE
+$3.96M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$3.82M
5
BPMC
Blueprint Medicines
BPMC
+$3.26M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$11.8M
2
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$6.24M
3
CEMP
Cempra, Inc.
CEMP
+$4.45M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.56M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 87.84%
2 Miscellaneous 12.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$8.53B
$3.58M 1.5%
300,000
+40,000
+15% +$505K
INDP icon
27
Indaptus Therapeutics
INDP
$155M
$3.38M 1.41%
281
– –
AMRN
28
Amarin Corp
AMRN
$297M
$3.33M 1.39%
88,000
– –
NBIX icon
29
Neurocrine Biosciences
NBIX
$15.8B
$3.11M 1.3%
55,000
-70,000
-56% -$3.56M
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$3.05M 1.28%
250,000
-60,000
-19% -$935K
AGRX
31
DELISTED
Agile Therapeutics
AGRX
$2.93M 1.22%
150
-43
-22% -$680K
CORI
32
DELISTED
Corium International, Inc.
CORI
$2.88M 1.21%
+355,000
New +$2.79M
TRIL
33
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.65M 1.11%
210,000
-35,275
-14% -$490K
XENE icon
34
Xenon Pharmaceuticals
XENE
$6B
$2.41M 1.01%
300,000
+148,700
+98% +$1.27M
XOMA
35
DELISTED
Xoma
XOMA
$2.26M 0.95%
85,000
-62,500
-42% -$1.6M
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$2.21M 0.92%
150,000
-100,000
-40% -$1.34M
ALDR
37
DELISTED
Alder Biopharmaceuticals
ALDR
$2.15M 0.9%
65,000
+48,900
+304% +$1.65M
NBRV
38
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.12M 0.88%
+880
New +$2.15M
CYTO
39
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.83M 0.77%
5
+1
+25% +$288K
TENX icon
40
Tenax Therapeutics
TENX
$82M
$1.77M 0.74%
17
-3
-15% -$311K
CYNA
41
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$1.68M 0.7%
110,000
+81,000
+279% +$1.23M
AXDX
42
DELISTED
Accelerate Diagnostics
AXDX
$1.61M 0.67%
7,500
-2,000
-21% -$365K
CLLS
43
Cellectis
CLLS
$358M
$1.55M 0.65%
+50,000
New +$1.52M
MGNX icon
44
MacroGenics
MGNX
$260M
$1.08M 0.45%
+35,000
New +$1.06M
VTAE
45
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$1.06M 0.44%
+58,500
New +$805K
IMMU
46
DELISTED
Immunomedics Inc
IMMU
$890K 0.37%
+290,000
New +$809K
SGMO
47
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$548K 0.23%
+60,000
New +$462K
EVOK
48
DELISTED
Evoke Pharma
EVOK
$429K 0.18%
903
-903
-50% -$459K
BLRX
49
BioLineRX
BLRX
$12.1M
$325K 0.14%
417
– –
CMRX
50
DELISTED
Chimerix, Inc.
CMRX
– –
-310,000
Closed -$11.8M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2015 Portfolio in Review

As of Q4 2015, Opaleye Management held 60 positions worth $239M, up 18% from $203M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Opaleye Management deployed $7.18M of net new capital in Q4 2015, opening 11 new positions and adding to 16 existing holdings. Its largest new stake was Assertio: 5,000 shares worth $5.44M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Cempra, Inc., an estimated $4.45M trimmed.

  • Opaleye Management's largest Q4 2015 buy was Assertio: 5,000 shares worth $5.44M.
  • Opaleye Management added most to Sage Therapeutics in Q4 2015, an estimated $3.96M increase.
  • Opaleye Management's biggest Q4 2015 reduction was Cempra, Inc., cutting an estimated $4.45M.
  • Opaleye Management fully exited Chimerix, Inc. in Q4 2015, selling an estimated $11.8M.
  • Opaleye Management's ten largest holdings make up 38% of its $239M portfolio in Q4 2015.
  • Opaleye Management opened 11 new positions and closed 7 in Q4 2015.
  • Opaleye Management's portfolio value rose 18% quarter-over-quarter to $239M.

Based on Opaleye Management's 13F filing for Q4 2015, filed 12 Feb 2016.